Two-drug treatment for GSK HIV meets the primary goal in late-stage studies

(Reuters) – GlaxoSmithKline said on Thursday that its treatment of two drugs for HIV, the virus that causes AIDS, met its main goal in the latest stage studies.

FILE PHOTO: The GlaxoSmithKline logo (GSK) is seen at the top of GSK Asia House in Singapore, on March 21, 2018. Photograph taken on March 21, 2018. REUTERS / Loriene Perera

The studies were designed to evaluate the safety and efficacy of the combination of two drugs, which aims to reduce the side effect of current treatments that combine three or four medications.

The safety results for the new treatment of HIV, a once-a-day fixed dose that combines two previously approved drugs, dolutegravir and rilpivirine, were consistent with the labeling of the product for the drugs, said ViiV Healthcare, majority ownership of GSK.

Report of Arathy S Nair in Bengaluru; Edition of Alexander Smith


Source link

Check Also

First West Nile mosquito of 2018 collected in Dauphin County

The Dauphin County Conservation District has collected its first mosquito sample infected with the West …